Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: Long-term efficacy results: A Hellenic Cooperative Oncology Group (HeCOG) study
Kosmidis, Paraskevas A.
Dimopoulos, M. A.
Stathopoulos, G. P.
Kalofonos, H. P.
Skarlos, Dimosthenis V.
SourceAnnals of Oncology
Google Scholar check
MetadataShow full item record
Background: We compared the combination plus Carboplatin plus paclitaxel, which is considered the treatment of choice for initial chemotherapy of advanced ovarian cancer (AOC) with a regimen combining alternating carboplatin and cisplatin plus paclitaxel. The two platinum derivatives have been previously combined as they are not totally cross-resistant and as they share no overlapping toxicities. Patients and methods: Patients with AOC, after the initial cytoreductive surgery were randomized to either 6 courses of paclitaxel at 175 mg/m2 as 3h infusion plus Carboplatin at 7 AUC (Arm A) or Paclitaxel at the same dose plus Carboplatin again at 7 AUC for cycles 1,3,5, while for cycles 2,4,6 Cisplatin at 75 mg/m2 substituted for Carboplatin (Arm B). Results: 247 patients are analyzed. Significant differences were not found, both in terms of PFS (38 vs 39 months, p=0.95) and overall survival (40.6 vs 38.6 months, p=0.79). There was not also difference in 5-year survival rate (35% vs 39%) or 5-year PFS rate (23% vs 28%). Age >60, PS 2, stage IV disease and presence of residual disease were adversely related to the overall survival. Conclusion: Both regimens are well tolerated and effective. Alternating cisplatin with carboplatin does not improve the results compared with the standard combination. © 2005 European Society fr Medical Oncology.
Showing items related by title, author, creator and subject.
Jr, H. A. Azim; Santoro, L.; Russell-Edu, W.; Pentheroudakis, George; Pavlidis, Nicholas; Peccatori, Fedro A. (2012)Background: Pregnancy-associated breast cancer (PABC) is relatively rare with considerable controversy regarding its prognosis. Patients & methods: Two of the authors independently performed a literature search with no ...
Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG) Papaxoinis, G.; Papageorgiou, S.; Rontogianni, D.; Kaloutsi, V.; Fountzilas, George; Pavlidis, Nicholas; Dimopoulos, M. A.; Tsatalas, C.; Xiros, N.; Economopoulos, T. (2006)The aim of this retrospective study was to illustrate the clinicopathologic data and the treatment results in patients with primary gastrointestinal tract non-Hodgkin's lymphoma (GI NHL). Among 810 patients with NHL, 128 ...
Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: A study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial Pliarchopoulou, K.; Kalogeras, K. T.; Kronenwett, R.; Wirtz, R. M.; Eleftheraki, A. G.; Batistatou, Anna; Bobos, M.; Soupos, N.; Polychronidou, G.; Gogas, H.; Samantas, E.; Christodoulou, C.; Makatsoris, T.; Pavlidis, Nicholas; Pectasides, Dimitrios; Fountzilas, George (2013)Purpose: RACGAP1 is a Rac GTPase-activating protein involved in cell growth regulation, cell transformation and metastasis. The aim of the present study was to explore the prognostic and/or predictive significance of RACGAP1 ...